Laki Power Closes Financing Led By Brunnur Ventures
28.10.2019 09:00:00 EET | Business Wire | Press release
Laki Power (www.lakipower.com), a leader in real-time surveillance for high-voltage powerline infrastructure, announced today the successful closing of its first institutional investment round, led by Brunnur Ventures. The new capital will support further development of the Company’s high-voltage powerline sensor product portfolio, powered by its unique patent-pending line energy harvesting platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191027005046/en/
Inductively powered and sited directly on the phase wire, our LKX-range of sensors provides fully-autonomous, next-generation monitoring capabilities for high-voltage transmission and distribution infrastructure. (Photo: Business Wire)
“We’re pleased to announce the closing of this funding and are delighted to be working with the experienced team at Brunnur Ventures,” said Sigurjon Magnusson, CEO at Laki Power. “This round enables us to accelerate the build out of our power harvesting capabilities into an expanded range of high-value products and services that address the rapidly growing needs of power grid operators for real-time knowledge of system health and functionality.”
Electricity grids worldwide are changing, driven by the increased demands of distributed generation of wind and solar, and pressure from both customers and regulators for increased resilience, transparency and accountability.
“Addressing the need for real-time, actionable intelligence for the monitoring and management of power grid infrastructure is clearly a huge opportunity and we are seeing that utilities are deploying sensing and monitoring systems more broadly, and faster than ever before,” commented Arni Blöndal, General Partner at Brunnur Ventures.
Unique capabilities
Laki Power’s unique products are powered by the only on-market energy harvester that supports multiple sensors and communications devices with full autonomy from external power sources, eliminating the need for solar, wind or diesel generators. The Company’s PowerGRAB™ technology harvests energy from the electromagnetic field surrounding the alternating current (AC) carrying phase wires of high voltage power lines to provide direct current (DC) power for running external and internal surveillance and monitoring devices, and many other applications that need clean and stable DC power.
About Laki Power
Laki Power was founded in 2015 to transform the way line monitoring is carried out for transmission system operators (TSOs) and distribution system operators (DSOs), by bringing to market new technology that dramatically enhances the level of power that can be efficiently harvested from high voltage lines.
Electrical transmission and distribution systems worldwide span millions of kilometres. Yet despite carrying huge amounts of energy, tapping into that energy, to provide monitoring devices with power in the remote places that these lines cross, has remained a persistent challenge. Instead these systems have relied on local fossil fuel generators, wind turbines, solar cells or power from the line that requires a mini-substation to adapt voltage and power levels for proper utilization. This results in very high costs of installing, maintaining and resupplying these systems, as well as a host of other environmental, operational, logistical and maintenance issues.
Laki Power's patent pending technology can harvest up to hundred times more power than competitor solutions, offering unprecedented monitoring capacity and flexibility for a range of sensors and applications.
For more information, please visit: www.lakipower.com
About Brunnur Ventures
Brunnur Ventures is a $30m venture capital fund focused on Icelandic start-up companies, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent.
For more information, please visit: www.brunnurventures.com
Laki Power and the Laki Power logo are registered trademarks of Laki Power in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191027005046/en/
Contact information
Sigurjon Magnusson
CEO, Laki Power
sigurjon.magnusson@lakipower.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom